JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies for … [Read more…]

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general … [Read more…]

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company’s common stock … [Read more…]

Federal Court Grants WHOOP Preliminary Injunction Against Lexqi

Injunction orders Lexqi to halt U.S. Sales of wearable health tracker BOSTON–(BUSINESS WIRE)–WHOOP, the human performance company, today announced that the U.S. District Court for the District of Massachusetts has granted a motion by WHOOP for a preliminary injunction against Shenzhen Lexqi Electronic Technology Co., Ltd. (Lexqi). The injunction, issued in a trade dress infringement … [Read more…]

BioSelective Capital Investments Completes Acquisition of BioDuro’s Irvine, California Drug Product Development and Manufacturing Operations

PARK CITY, Utah & IRVINE, Calif.–(BUSINESS WIRE)–BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, today announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets. … [Read more…]

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568). CD37 is a transmembrane protein that plays … [Read more…]

LINVO AG Sponsors Fight Aids Cup 2026 in Monaco

Football legends unite with royalty for HIV awareness at Stade Louis II ZURICH–(BUSINESS WIRE)–When Leonardo Bonucci, Andriy Shevchenko and Clarence Seedorf lined up alongside Formula 1 star Charles Leclerc on January 24, 2026, it wasn’t for a trophy – it was for a cause. LINVO AG proudly sponsored Cirque FC at the sixth annual Fight … [Read more…]

Veradermics Announces Pricing of Upsized Initial Public Offering

NEW HAVEN, Conn.–(BUSINESS WIRE)–Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the … [Read more…]

AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference … [Read more…]

Transcat Reports Strong Fiscal Third Quarter 2026 Financial Results with a Return to High Single-Digit Service Organic Revenue Growth*

Q3’26 Revenue Increased 26% to $83.9 Million Q3’26 Service Revenue Increased 29% to $53.7 Million Q3’26 Distribution Revenue Grew 20% to $30.2 Million on Increased Demand for Rentals Q3 ’26 Gross Margin Expanded 60 Basis Points to 30.1% Management Reaffirms Fiscal 2026 Service Revenue Expectations Management to Host Conference Call Today at 4:30 p.m. Eastern … [Read more…]